Keytruda (pembrolizumab)

pCPA File Number: 22073
Negotiation Status:
Concluded with an LOI
Indication(s):
Stage IIB or IIC melanoma following complete resection, for adjuvant treatment of adult and pediatric (12 years and older) patients
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0286-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: